Regina García Delgado

A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies

Mark A. Dawson, Gautam Borthakur, Brian J.P. Huntly et al. · Clinical Cancer Research · 2022 · 36 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)

Pankit Vachani, Andrzej Lange, Regina García Delgado et al. · Blood · 2021 · 23 citations

Medicine, Pharmacology, Pharmacotherapy +4

Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5

Marc E. Rothenberg, Florence Roufosse, Stanislas Faguer et al. · The Journal of Allergy and Clinical Immunology In Practice · 2022 · 22 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +13

Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score

José Falantes, Regina García Delgado, Cristina Calderón‐Cabrera et al. · Leukemia Research · 2014 · 18 citations · Full text

Pharmacy, Pharmacotherapy, Risk Assessment +8

Eltrombopag Treatment of Thrombocytopenia in Advanced Myelodysplastic Syndromes and Acute Myeloid Leukemia: Results of the 8-Week Open-Label Part of an Ongoing Study

Moshe Mittelman, Sarit Assouline, Evangelos Briasoulis et al. · Blood · 2012 · 11 citations

Medicine, Hematology, Pharmacotherapy +16